CoLiQ is a clinical study designed to evaluate the clinical usefulness of circulating tumor DNA (ctDNA) markers found in blood, as a liquid biopsy for diagnosis, prognosis and follow-up of colorectal cancer. The main questions it aims to answer are: 1) Can a panel of ctDNA markers identify CRC patients among the other patients summoned for colonoscopy? and 2) Does the type, number and level of ctDNA markers vary with the subtype and clinical course of CRC? Participants will be asked to answer a questionnaire and give a blood sample at inclusion. In addition, patients with CRC will be asked to give an extra test tube at their routine treatment and follow-up blood sampling.
Study Type
OBSERVATIONAL
Enrollment
3,000
based on a panel of circulating tumor DNA markers
Nord-Trøndelag Hospital Trust
Levanger, Norway
RECRUITINGColorectal cancer
Number of patients with colorectal cancer at histology following colonoscopy
Time frame: evaluated within 3 months after colonoscopy
Colorectal adenoma
Number of patients with colorectal adenoma at histology following colonoscopy
Time frame: evaluated within 3 months after colonoscopy
Inflammatory bowel disease
Number of patients with inflammatory bowel disease at histology following colonoscopy
Time frame: evaluated within 3 months after colonoscopy
Recurrence
Recurrence of colorectal cancer among patients treated curatively.
Time frame: Within 5 years following treatment with curative intent for colorectal cancer
Death
Death among patients with colorectal cancer
Time frame: Within 5 years following diagnosis of colorectal cancer
Treatment response
Treatment response among colorectal cancer patients as measured by todays standards of follow-up (CEA, CT-scans, colonoscopy)
Time frame: Within the 5 years following diagnosis of colorectal cancer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.